Authors

Latest:

Experts Discuss the Management of Paronychia When Treating Patients with EGFR TKIs

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the management of paronychia when treating patients with EGFR TKIs.

Xichun Hu, MD, PhD

Latest:

Dr Hu on the Evaluation of Tibremciclib Plus Fulvestrant in HR+/HER2– Advanced Breast Cancer

Xichun Hu, MD, PhD, discusses a study of tibremciclib plus fulvestrant in HR+/HER2– advanced breast cancer following progression on endocrine therapy.

Kristen A. Marrone, MD, Johns Hopkins Medicine

Latest:

Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLC

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

Daniel J. Hausrath, MD

Latest:

The Podcast by Fellows for Fellows

Daniel J. Hausrath, MD, discusses a collaborative effort to produce a podcast for fellows that reviews the fundamentals, core concepts, and important management approaches in the field, as determined by the latest evidence and expert opinion.

Cristina DeCesaris, MD

Latest:

Dr. DeCesaris on Classical vs Contemporary Indications for Radiation in Breast Cancer

Cristina DeCesaris, MD, discusses classical indications for breast cancer radiation and how these methods are being contextualized in the contemporary treatment era.

Vered Stearns, MD

Latest:

Dr Stearns on the Role of Carboplatin in Early-Stage TNBC

Vered Stearns, MD, discusses the role of carboplatin in early-stage triple-negative breast cancer according to results from the phase 3 PEARLY trial.

Kirsten L. Greene, MD, MAS, FACS

Latest:

Dr. Greene on the Future of Personalized Therapy in Prostate Cancer

Kirsten L. Greene, MD, MAS, FACS, discusses the future of personalized therapy in prostate cancer.

Matthew J. Wieduwilt, MD, PhD

Latest:

Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALL

Novel approaches with highly active, minimally toxic agents are needed to improve upon traditional chemotherapy and possibly eliminate chemotherapy altogether in the treatment of patients with acute lymphoblastic leukemia.

Ahmad Abdelfattah Al-Hader, MD

Latest:

Student Loan Debt, Immigration Status Often Drive Career Decisions for Fellows

Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.

Beth M. Faiman, PhD, CNP, Cleveland Clinic

Latest:

Impact of Clinical Trials on the Management of Multiple Myeloma

Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.

Ana Alfonso Piérola, MD, PhD

Latest:

Dr Alfonso Piérola on Unmet Needs in Higher-Risk MDS

Ana Alfonso Piérola, MD, PhD, discusses unmet needs for patients with high-risk myelodysplastic syndrome.

Praveen Vikas, MBBS

Latest:

MRD and ctDNA Could Shift into Larger Role to Guide Treatment Decisions in Breast Cancer

Praveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.

Matthew J. Frigault, MD

Latest:

Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, Lymphomas

Matthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.

Estelamari Rodriguez, MD, MPH

Latest:

Overcoming Disparities in Cancer Care

Estelamari Rodriguez, MD, MPH, discusses how to overcome disparities in cancer care.

Meral Beksac, MD

Latest:

Dr Beksac on OS Data From the OPTIMISMM Trial in Relapsed/Refractory Multiple Myeloma

Meral Beksac, MD, discusses overall survival data from the phase 3 OPTIMISMM trial in relapsed/refractory multiple myeloma.

Al B. Benson III, MD, FACP, FACCC, FASCO

Latest:

Future Outlooks in the Treatment of Metastatic Colorectal Cancer

Experts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.

Rona Yaeger, MD

Latest:

Dr Yaeger on the Implications of Data With Second-Line Sotorasib Plus Panitumumab in mCRC

Rona Yaeger, MD, discusses the implications of data with second-line sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Nicholas McAndrew, MD, MSCE, UCLA Health

Latest:

Dr McAndrew on the HER2CLIMB-02 Trial in HER2+ Breast Cancer

Nicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.

Gerald Prager, MD, Medical University of Vienna

Latest:

Future Directions for mCRC Management

Gerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.

Haley M. Hill, PA-C

Latest:

Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.